ImmunityBio

Inducing Immunogenic Cell Death By Orchestrating the Innate (NK) and Adaptive (T Cell) Immune System

Careers

Join our fast-growing immunotherapy company. We offer you the chance to work with a team that is focused on building something impactful.

About Us

ImmunityBio, Inc. is a privately held immunotherapy company with one of the broadest portfolios of biological molecules spanning albumin-linked chemotherapeutic, peptides, fusion proteins, cytokine, monoclonal antibodies, adenovirus and yeast vaccine therapies.

Recent News

Jan. 16, 2020
Progress Report on Cancer Breakthroughs 2020 Project Presented by Dr. Soon-Shiong at J.P. Morgan Healthcare Conference

About Us

ImmunityBio, Inc. is a privately held immunotherapy company with one of the broadest portfolios of biological molecules spanning albumin-linked chemotherapeutic, peptides, fusion proteins, cytokine, monoclonal antibodies, adenovirus and yeast vaccine therapies.

Careers

Join our fast-growing immunotherapy company. We offer you the chance to work with a team that is focused on building something impactful.

Recent News

Dec. 16, 2019
NantKwest and ImmunityBio Present Results of Landmark Trial of First-in-Human Natural Killer Cell Combination Immunotherapy

Contact Us

ImmunityBio, Inc.

© 2020 ImmunityBio, Inc. All rights reserved.

Privacy | Terms of Use.

© 2020 ImmunityBio, Inc. All rights reserved.

Privacy | Terms of Use.